The Pharma Data

JANUARY 27, 2021

CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT ) (“ XPhyto ” or the “ Company “) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. Pending positive results, the Company plans to advance the products toward a final pivotal study and application for regulatory approval.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

XTalks

AUGUST 30, 2022

According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013. Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019. Intrathecal Chemotherapy.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

JANUARY 3, 2021

to have in place 25 operating production lines of which 5 to 10 are expected to be GMP production lines. The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. over 90 percent gross margin. to be cash flow positive.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 26, 2020

There are significant challenges in drug development in this space and we look forward to working closely with pharma and biotech partners to discover how we can add value to their programs, provide patient benefit and competitive product differentiation.” ” Prof. Finnish time. About Nanoform.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 3, 2023

While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry. As with any pharmaceutical manufacturing, challenges can be many, and processes are highly regulated.

Contamination 130

Contamination Manufacturing Containment Production 130